HVA vs IA/DA or VA in the Treatment of ND HR-AML
The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Guopan Yu
- Phone Number: +8615876559968
- Email: yugpp@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Recruiting
- Department of Hematology,Nanfang Hospital, Southern Medical University
-
Contact:
- Guopan Yu
- Phone Number: +8615876559968
- Email: yugpp@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- According to the world health organization (WHO) classification of newly diagnosed with AML patients;
- Age ≥18 years old;
- High-risk patients should meet any of the following criteria: ① High risk group according to the European Leukemia Risk stratification (ELN) 2022; (2) Secondary AML (sAML) which develops from myelodysplastic syndrome (MDS), bone marrow hyperplastic tumor (MPN) or chronic myeloid cell leukemia, et.; (3) Treatment-related AML (t-AML), Patients have a history of cytotoxic treatment record or ionizing radiation therapy.
- Patients did not receive anti-AML therapy (except leukopenia therapy, such as hydroxyurea or cytarabine < 1.0g/d) after the diagnosis of AML;
- Expected survival ≥12 weeks;
- The eastern tumor cooperation group (ECOG) score 3 points or less;
- Kidney function: creatinine clearance acuity 30 ml/min;
- Liver function: ALT < 5 times normal value, bilirubin < 3 times normal value;
- Sign the informed consent form and understand and abide by the plan calls for process.
Exclusion Criteria:
- Acute promyelocytic leukemia;
- With central nervous system leukemia (CNSL) ;
- The cardiac function > level 2;
- The AIDS virus (HIV) infection;
- Other clinical significance of uncontrolled condition, including but not limited to: (1) out of control, or active systemic infection (viruses, bacteria or fungi); (2) chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; (3) need to actively deal with the merger of the second tumor;
- Can't take oral treatment or having a gastrointestinal disease impact ing the absorption;
- Being allergy to the experimental drugs;
- Pregnant and lactating women;
- Patients who could not understand or adhere to the study protocol;
- Patients deemed by the investigator to be ineligible for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: IC regiment for Fit-AML
|
Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine).
IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.
|
|
Experimental: HVA regiment for Fit-AML
|
Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14.
Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
|
|
Active Comparator: VA regiment for unfit-AML
|
VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.
|
|
Experimental: HVA regiment for unfit-AML
|
Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14.
Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite complete remission (CRc)
Time Frame: At the end of cycle 2 (each cycle is 28 days).
|
CRc includes complete remission (CR) and complete remission accompanied with with incomplete count recovery (CRi).
|
At the end of cycle 2 (each cycle is 28 days).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DOR
Time Frame: 1 year
|
duration of response
|
1 year
|
|
Complete remission (CR)
Time Frame: At the end of cycle 2 (each cycle is 28 days).
|
Complete remission is defined as BM with >5% blasts and without extramedullary infltration and recovery of peripheral blood cells.
|
At the end of cycle 2 (each cycle is 28 days).
|
|
Overall response rate (ORR)
Time Frame: At the end of cycle 2 (each cycle is 28 days).
|
ORR includes CRc, partial response (PR), and morphologic leukemia-free state (MLFS).
|
At the end of cycle 2 (each cycle is 28 days).
|
|
Rate of Measurable residual disease (MRD) negative
Time Frame: At the end of cycle 2 (each cycle is 28 days).
|
MRD is monitored using flow cytometric analysis with a positive MRD threshold of 0.1%.
|
At the end of cycle 2 (each cycle is 28 days).
|
|
Overall survival (OS)
Time Frame: 1 year
|
OS is calculated from enrollment to death or the last follow-up.
|
1 year
|
|
Event-free survival (EFS)
Time Frame: 1 year
|
EFS is calculated from enrollment to the date of relapse or death or the last follow-up.
|
1 year
|
|
Adverse events (AE)
Time Frame: The first dose until 28 days after treatment discontinuation
|
AE are recorded from the first dose until 28 days after treatment discontinuation and are graded according to the NCI Common Terminology Criteria for Adverse Events version 5.0.
|
The first dose until 28 days after treatment discontinuation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Guopan Yu, Nanfang Hospital, Southern Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2024-576
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.